Related Experiment Video

Updated: Jul 13, 2025

Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering
09:43

Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering

Published on: November 22, 2019

6.3K

Hutchinson-Gilford progeria syndrome: Cardiovascular manifestations and treatment

Jing Lian1, Linfang Du1, Yang Li2

  • 1Medical School of Yan'an University, Yan'an, China.

Mechanisms of Ageing and Development
|October 13, 2023
PubMed

Insights

Hutchinson-Gilford progeria syndrome (HGPS) accelerates aging due to LMNA gene mutations, causing premature death from cardiovascular disease. This study explores HGPS as a model for aging-related heart conditions.

Area of Science:

  • Cardiovascular Biology
  • Genetics
  • Aging Research

Background:

  • Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by LMNA gene mutations, leading to progerin accumulation and rapid aging.
  • HGPS patients exhibit severe cardiovascular phenotypes resembling physiological aging, including atherosclerosis and heart abnormalities, despite lacking traditional risk factors.
  • The unique presentation of cardiovascular disease in HGPS offers a novel model for studying age-related cardiovascular pathologies.

Purpose of the Study:

  • To analyze the pathogenesis and pathophysiological characteristics of HGPS.
  • To elucidate the relationship between HGPS and cardiovascular disease.
  • To provide insights into molecular mechanisms and potential treatment strategies for cardiovascular complications in HGPS.

Main Methods:

  • Review and analysis of existing literature on HGPS pathogenesis and cardiovascular manifestations.
  • Examination of molecular mechanisms underlying cardiovascular disease in HGPS patients.
  • Summarization of disease models utilized in HGPS research.

Main Results:

  • HGPS pathogenesis involves LMNA gene mutations and progerin expression, leading to accelerated aging and cardiovascular complications.
  • Cardiovascular phenotypes in HGPS mirror accelerated physiological aging, characterized by atherosclerosis, vascular lesions, and cardiac dysfunction.
  • HGPS serves as a valuable model for understanding aging-related cardiovascular disease, independent of traditional risk factors.

Conclusions:

  • Understanding HGPS pathogenesis is crucial for developing targeted therapies for its cardiovascular complications.
  • Further research into HGPS disease models can enhance comprehension of cardiovascular aging mechanisms.
  • HGPS research provides critical insights into the molecular basis of cardiovascular disease and aging.

Keywords:
AgingCardiovascular diseaseHGPSProgerin

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.2K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

687

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
14
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
194